International Journal of Colorectal Disease

, Volume 24, Issue 1, pp 19–25

Positive impact of blocking tumor necrosis factor α on the nutritional status in pediatric Crohn’s disease patients

  • A. Diamanti
  • M. S. Basso
  • M. Gambarara
  • B. Papadatou
  • F. Bracci
  • C. Noto
  • M. Castro
Original Article

Abstract

Background

TNFα seems to contribute to inflammation and malnutrition in Crohn’s disease (CD) patients. In CD patients, the comparative effects on nutritional status of infliximab and traditional therapy have not yet been determined. The aim of our study was to assess the effects of infliximab as compared with those of standard therapy on nutritional status, disease activity, resting energy expenditure (REE), and food intake in CD children and adolescents.

Methods

From September 1999 to September 2005, all CD patients treated with infliximab (group A) were reviewed and matched with CD patients treated with traditional therapy (mesalazine and azathioprine) (group B).

Results

Fourteen CD patients from group A and 14 from group B were included; median interval before follow-up investigation was 10 months. Baseline and final values of weight, height, body mass index (BMI), pediatric CD activity index (pCDAI), REE, and food intake were studied. In treated patients, but not in control group, mean baseline weight (kg) and BMI values, 39.7 ± 13.1 and 17.9 ± 3.3, respectively, were significantly lower than their final values 42.6 ± 13.2 and 18.9 ± 3.1, and median pCDAI values 23.5 were significantly higher than their final values 10 (P < 0.05). Significant changes in height, REE, and food intake were not found in either group.

Conclusions

In pediatric CD patients, infliximab seems to impact positively on the nutritional status as demonstrated by the improvement in weight and BMI, but not in linear growth; effects on nutritional status seem to be due to amelioration of disease activity, rather than to REE reduction or food intake increase.

Keywords

TNFα Crohn’s disease Children Infliximab Nutritional status Humans 

References

  1. 1.
    Cezard JP, Touati G, Alberti C et al (2002) Growth in pediatric Crohn’s disease. Horm Res 58:11–15PubMedCrossRefGoogle Scholar
  2. 2.
    Savage MO, Beattie RM, Camacho-Hubner C et al (1999) Growth in Crohn’s disease. Acta Paediatrica 88:89–92CrossRefGoogle Scholar
  3. 3.
    Griffiths AM, Phoungbich N, Smith C et al (1993) Growth and clinical course of children with Crohn’s disease. Gut 34:939–943PubMedCrossRefGoogle Scholar
  4. 4.
    Newby EA, Sawczenko A, Thomas AG, Wilson D (2005) Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev 20(3):CD003873Google Scholar
  5. 5.
    Walters TD, Gilman AR, Griffiths AM (2007) Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis 13(4):424–430PubMedCrossRefGoogle Scholar
  6. 6.
    Söderholm JD, Streutker C, Yang PC et al (2004) Increased epithelial uptake of protein antigens in the ileum of Crohn’s disease mediated by tumor necrosis factor α. Gut 53:1817–1824PubMedCrossRefGoogle Scholar
  7. 7.
    Gibson PR (2004) Increased gut permeability in Crohn’s disease: is TNF the link. Gut 53:1724–1725PubMedCrossRefGoogle Scholar
  8. 8.
    Yan F, John SK, Wilson G et al (2004) Kinase suppressor of Ras-1 protects intestinal epithelium from cytokine-mediated apoptosis during inflammation. J Clin Invest 114(9):1272–1280PubMedGoogle Scholar
  9. 9.
    Escher JC, Taminiau JAJM, Nieuwenhuis EES et al (2003) Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9:34–58PubMedCrossRefGoogle Scholar
  10. 10.
    Kleinman RE, Baldassano RN, Caplan A et al (2004) Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 39:15–27PubMedCrossRefGoogle Scholar
  11. 11.
    Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305–311PubMedCrossRefGoogle Scholar
  12. 12.
    Baldassano R, Braegger CP, Escher JC et al (2003) Infliximab therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 98:833–838PubMedCrossRefGoogle Scholar
  13. 13.
    Borrelli O, Bascietto C, Viola F et al (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 36:342–347PubMedCrossRefGoogle Scholar
  14. 14.
    Tynjala P, Lahdenne P, Vahasalo P et al (2006) Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65:1044–1049PubMedCrossRefGoogle Scholar
  15. 15.
    Hyams J, Crandall W, Kugathasan S et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132(3):863–873PubMedCrossRefGoogle Scholar
  16. 16.
    Franchimont D, Roland S, Gustot T et al (2005) Impact of infliximab on serum leptin levels in patients with Crohn’s disease. J Clin Endocrinol Metab 90:3510–3516PubMedCrossRefGoogle Scholar
  17. 17.
    NASPGHAN (2007) Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the NASPGHAN and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 44:653–674CrossRefGoogle Scholar
  18. 18.
    IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (2005) Inflammatory bowel disease in children and adolescents: recommendations for diagnosis—the Porto criteria. J Pediatr Gastroenterol Nutr 41(1):1–7CrossRefGoogle Scholar
  19. 19.
    Hyams JS, Ferry GD, Mandel FS et al (1991) Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 12:439–447PubMedGoogle Scholar
  20. 20.
    Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT 1 randomised trial. Lancet 342:174–175Google Scholar
  21. 21.
    Levine A, Broide E, Stein M et al (2002) Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn’s disease. J Pediatr 140:75–80PubMedCrossRefGoogle Scholar
  22. 22.
    Schofield W (1985) Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 39:5–41PubMedGoogle Scholar
  23. 23.
    Food and Nutrition Board, National Research Council (1989) Recommended Dietary Allowances, 10th edn. National Academy Press, Washington, DCGoogle Scholar
  24. 24.
    Kundhal P, Zachos M, Holmes JL, Griffiths AM (2001) Controlled ileal release budesonide in pediatric Crohn’s disease: efficacy and effects on growth. J Pediatr Gatroenterol Nutr 33:75–80CrossRefGoogle Scholar
  25. 25.
    Markowitz J, Grancher K, Kohn N et al (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 119:895–902PubMedCrossRefGoogle Scholar
  26. 26.
    Berni Canani R, Terrin G, Borrelli O et al (2006) Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis 38(6):381–387PubMedCrossRefGoogle Scholar
  27. 27.
    Cezard JP, Nouaili N, Talbotec C et al (2003) A prospective study of the efficacy and tolerance of chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn’s disease. J Pediatr Gatroenterol Nutr 36:632–636CrossRefGoogle Scholar
  28. 28.
    deRidder L, Escher J, Bouquet J et al (2004) Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gatroenterol Nutr 39:46–52CrossRefGoogle Scholar
  29. 29.
    Ballinger A (2002) Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 58:7–10PubMedCrossRefGoogle Scholar
  30. 30.
    Hart JW, Bremner AR, Wootton SA, Beattie RM (2005) Measured versus predicted energy expenditure in children with inactive Crohn’s disease. Clin Nutr 24:1047–1055PubMedCrossRefGoogle Scholar
  31. 31.
    Azcue M, Rashid M, Griffiths A, Pencharz PB (1997) Energy expenditure and body composition in children with Crohn’s disease: effect of enteral nutrition and treatment with prednisolone. Gut 41:203–208PubMedCrossRefGoogle Scholar
  32. 32.
    Varille V, Cezard JP, de Lagausie P, Bellaiche M et al (1996) Resting energy expenditure before and after gut resection of gut lesions in pediatric Crohn’s disease. J Pediatr Gatroenterol Nutr 9:13–9CrossRefGoogle Scholar
  33. 33.
    Kushner RF, Schoeller DA (1991) Resting energy expenditure in patients with inflammatory bowel disease. Am J Clin Nutr 53:161–165PubMedGoogle Scholar
  34. 34.
    Andrassy RJ, Chwals WJ (1998) Nutritional support of the pediatric oncology patient. Nutrition 14:124–129PubMedCrossRefGoogle Scholar
  35. 35.
    Cole TJ (2004) Children grow and horses race: is the adiposity rebound a critical period for later obesity. BMC Pediatrics 4:6–12PubMedCrossRefGoogle Scholar
  36. 36.
    Segal KR, Burastero S, Chun A et al (1991) Estimation of extracellular and total body water by multiple-frequency bioelectrical-impedance measurement. Am J Clin Nutr 54:26–29PubMedGoogle Scholar
  37. 37.
    Rosenbaum M, Leibel RL, Hirsch J (1997) Obesity. N Engl J Med 337:396–407PubMedCrossRefGoogle Scholar
  38. 38.
    Gordon CM, Goodman E, Emans SJ et al (2002) Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr 141:64–70PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • A. Diamanti
    • 1
  • M. S. Basso
    • 1
  • M. Gambarara
    • 1
  • B. Papadatou
    • 1
  • F. Bracci
    • 1
  • C. Noto
    • 1
  • M. Castro
    • 1
  1. 1.Gastroenterology and Nutrition UnitBambino Gesù Children’s HospitalRomeItaly

Personalised recommendations